Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VRP 700

Next Previous
Drug Profile

VRP 700

Alternative Names: VRP-700

Latest Information Update: 09 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unknown
  • Developer Verona Pharma
  • Class Antitussives
  • Mechanism of Action Sensory receptor cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cough

Highest Development Phases

  • No development reported Cough

Most Recent Events

  • 07 Oct 2025 Verona Pharma has been acquired by Merck & Co
  • 28 Sep 2016 VRP 700 is available for licensing as of 28 Sep 2016. http://www.veronapharma.com/joomla/index.php/products
  • 18 Feb 2016 No development reported - Phase-II for Cough in United Kingdom (Inhalation)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top